



ichroma™ AFP Neo

INTENDED USE

ichroma™ AFP Neo is a fluorescence immunoassay (FIA) for the quantitative determination of AFP (Alpha Feto Protein) in human whole blood/serum/plasma. It is useful as an aid in management and monitoring of primary hepatocellular carcinoma and non seminomatous testicular cancer.

For in vitro diagnostic use only.

INTRODUCTION

Alpha-fetoprotein (AFP) is a α 1-globulin family of human plasma proteins and a glycoprotein with a molecular weight approximately 70 kDa. AFP is produced primarily in the liver of developing fetus. It can be found in maternal blood and in amniotic fluid since it is secreted into fetal serum. A great increase of AFP concentration in several malignant diseases mostly is primary hepatocellular carcinoma and non-seminomatous testicular cancer. Some 70-90% of patients with primary hepatocellular carcinoma and nonseminomatous testicular cancer have been observed to have high levels of AFP. High concentration of AFP also have been found in a limited number of patients diagnosed with various diseases such as gastrointestinal tract cancer, viral hepatitis, chronic active hepatitis, alcoholic cirrhosis, and adenocarcinomas of lung, pancreas, and gall bladder. Since AFP is well known to be an important prognostic indicator of non-seminomatous testicular cancer, its most definitive role is on monitoring post-treatment clinical status and the post therapeutic evaluation of patients.

PRINCIPLE

The test uses a sandwich immunodetection method.

The detector antibodies in buffer bind to antigens in the sample, forming antigen-antibody complexes, and migrate onto nitrocellulose matrix to be captured by the other immobilized antibodies on test strip.

More antigens in the sample will form more antigen-antibody complexes which lead to stronger fluorescence signal by detector antibodies, which is processed by the instrument for ichroma™ tests to show AFP concentration in the sample.

COMPONENTS

ichroma™ AFP Neo consists of 'cartridges', 'detector tubes', and 'detector diluent'.

- The cartridge contains the membrane called a test strip which has anti-AFP at the test line and rabbit IgG at the control line. All cartridges are individually sealed in an aluminum foil pouch containing a desiccant, and they are further packaged in a box.
- The detector tube has a granule containing anti-AFP-fluorescence conjugate, anti-rabbit IgG-fluorescence

conjugate and sodium azide as a preservative in phosphate buffered saline (PBS). All detector tubes are packed in a pouch.

- The detector diluent contains tween 20 as a detergent, sodium azide as a preservative in Tris-HCl, and it is pre-dispensed in a vial. The detector diluent is packed in a box.

WARNINGS AND PRECAUTIONS

- For *in vitro* diagnostic use only.
- Follow the instructions and procedures described in this 'Instructions for use'.
- Use only fresh samples and avoid direct sunlight.
- Lot numbers of all the test components (cartridge, detector tube, detector diluent and ID chip) must match each other.
- Do not interchange the test components between different lots or use the test components after the expiration date, either of which might yield incorrect test result(s).
- Do not reuse cartridges or detector tubes. A cartridge should be used for testing one sample only. A detector tube should be used for processing of one sample only.
- The cartridge should remain sealed in its original pouch until just before use. Do not use a cartridge, if pouch is damaged or has already been opened.
- Frozen sample should be thawed only once. For shipping, samples must be packed in accordance with local regulations. Sample with hemolysis and/or hyperlipidemia must not be used.
- If test components and/or sample are stored in refrigerator, then allow cartridge, detector tube, detector diluent and sample to be at room temperature for approximately 30 minutes before use.
- The instrument for ichroma™ tests may generate slight vibration during use.
- Used cartridges, detector tubes, detector diluent and pipette tips should be handled carefully and discarded by an appropriate method in accordance with relevant local regulations.
- The detector tube and the detector diluent contain sodium azide (NaN_3), and it may cause certain health issues like convulsions, low blood pressure, low heart rate, loss of consciousness, lung injury and respiratory failure. Avoid contact with skin, eyes, and clothing. In case of contact, rinse immediately with running water.
- No Biotin interference was observed in **ichroma™ AFP Neo** when biotin concentration in the sample was up to 3,500 ng/mL. If a patient has been taking biotin at dosage of more than 300 mg a day, it is recommended to collect blood again 24 hours after discontinuation of biotin intake.
- **ichroma™ AFP Neo** will provide accurate and reliable results subject to the below conditions.
 - **ichroma™ AFP Neo** should be used only in conjunction with instrument for ichroma™ tests.
 - Have to use recommended anticoagulant.

Recommended anticoagulant

K₃ EDTA, Sodium heparin

LIMITATION OF THE TEST SYSTEM

- The test may yield false positive result(s) due to the cross-reactions and/or non-specific adhesion of certain sample components to the capture/detector antibodies.
- The test may yield false negative result(s) due to the non-responsiveness of the antigens to the antibodies which is the most common if the epitope is masked by some unknown components, so therefore not being able to be detected or captured by the antibodies. The instability or degradation of the antigens with time and/or temperature may also cause false negative result as it makes the antigens unrecognizable by the antibodies.
- Other factors may interfere with the test and cause erroneous results, such as technical/procedural errors, degradation of the test components/reagents or presence of interfering substances in the test samples.
- Any clinical diagnosis based on the test result must be supported by a comprehensive judgment of the concerned physician in conjunction with clinical symptoms and other relevant test results.

STORAGE AND STABILITY

Storage condition			
Component	Storage Temperature	Shelf life	Note
Cartridge	2 - 30°C	20 months	Disposable
Detector tube	2 - 30°C	20 months	Disposable
Detector diluent	2 - 30°C	20 months	Unopened
		20 months	Opened

- After the cartridge pouch is opened, the test should be performed immediately.

MATERIALS SUPPLIED

REF CFPC-156

Components of **ichroma™ AFP Neo**

- Cartridge box:
 - Cartridge 25
 - Detector tube 25
 - Detector diluent 1
 - ID chip 1
 - Instructions for use 1

MATERIALS REQUIRED BUT SUPPLIED ON DEMAND

Following items can be purchased separately with **ichroma™ AFP Neo**.

Please contact our sales division for more information.

- Instrument for **ichroma™** tests
 - ichroma™ Reader** **REF** FR203
 - ichroma™ II** **REF** FPRR021
 - ichroma™ III** **REF** FPRR037
 - ichroma™ M3** **REF** FPRR035
 - ichroma™-50** **REF** FPRR022
 - ichroma™-50 PLUS** **REF** FPRR036
- Printer **REF** FPRR007
- Boditech AFP Control** **REF** CFPO-248
- Boditech Tumor marker Control** **REF** CFPO-94

SAMPLE COLLECTION AND PROCESSING

The sample type for **ichroma™ AFP Neo** is human whole blood/serum/plasma.

- It is recommended to test the sample within 24 hours after collection when collected sample is stored at room temperature.
- The samples (serum, plasma) should be separated from the clot by centrifugation within 3 hours after the collection of whole blood.
- The samples (whole blood, serum, plasma) may be stored for a week at 2-8°C prior to being tested. If testing will be delayed more than a week, samples (serum, plasma) should be frozen at -20°C.
- The samples (serum, plasma) stored frozen at -20°C for 3 months showed no performance difference.
- However, the whole blood sample should not be kept in a freezer in any case.
- As a repeated freeze-thaw cycle may affect the test result, do not refreeze previously frozen samples.

TEST SETUP

- Check the contents of **ichroma™ AFP Neo**: Sealed cartridges, detector tubes, a detector diluent, an ID chip and an instructions for use.
- Ensure that the lot number of the cartridge matches that of the detector tube, the detector diluent as well as an ID chip.
- If the sealed cartridge, the detector tube and the detector diluent have been stored in a refrigerator, place them on a clean and flat surface at room temperature for at least 30 minutes before testing.
- Turn on the instrument for **ichroma™** tests.
- Insert the ID chip into the 'ID chip port'.
- Please refer to the instrument for **ichroma™** tests operation manual for complete information and operating instructions.

TEST PROCEDURE

► **ichroma™ Reader, ichroma™ II, ichroma™ M3**

Multi test mode

- Take 150 µL of the detector diluent using a pipette and dispense it to the detector tube containing a granule. When the granule form is completely dissolved in the tube, it becomes detection buffer. (The detection buffer must be used immediately. Do not exceed 30 seconds.)
- Take 30 µL of sample (whole blood/serum/plasma/control) using a pipette and dispense it to the detector tube.
- Close the lid of the detector tube and mix the sample thoroughly by shaking it about 20 times. (The sample mixture must be used immediately. Do not exceed 30 seconds.)
- Take 75 µL of the sample mixture and dispense it into the sample well of the cartridge.
- Leave the cartridge at room temperature for 15 minutes.

▲ Scan the sample-loaded cartridge immediately

when the incubation time is over. If not, it will cause inaccurate test result.

- 6) To scan the sample-loaded cartridge, insert it into the cartridge holder of the instrument for ichroma™ tests. Ensure proper orientation of the cartridge before pushing it all the way inside the cartridge holder. An arrow is marked on the cartridge especially for this purpose.
- 7) Press the 'Select' or tap the 'Start' button on the instrument for ichroma™ tests to start the scanning process.
(ichroma™ M3 is tested automatically after inserting.)
- 8) The instrument for ichroma™ tests will start scanning the sample-loaded cartridge immediately.
- 9) Read the test result on the display screen of the instrument for ichroma™ tests.

Single test mode

- 1) The test procedure is same with the 'Multi test mode 1) – 4)'.
- 2) Insert the sample-loaded cartridge into the holder of the instrument for ichroma™ tests. Ensure proper orientation of the cartridge before pushing it all the way inside the cartridge holder. An arrow is marked on the cartridge especially for this purpose.
- 3) Press the 'Select' or tap the 'Start' button on the instrument for ichroma™ tests.
(ichroma™ M3 is tested automatically after inserting.)
- 4) The cartridge goes inside the instrument for ichroma™ tests and will automatically start scanning the sample-loaded cartridge after 15 minutes.
- 5) Read the test result on the display screen of the instrument for ichroma™ tests.

► **ichroma™ III**

- 1) The test procedure is same with the 'Single test mode'.

► **ichroma™-50, ichroma™-50 PLUS**

- 1) Insert the tip array in the tip station.
- 2) Insert the detector tube in the reagent station and cover the reagent station to hold the detector tubes in place.
- 3) Open the lid of the detector diluent and insert the detector diluent in the diluent station.
- 4) Insert the cartridge magazine with the cartridges into the magazine station.
- 5) Insert the sample tube into the blood collection tube rack and load the blood collection tube rack into the sampling station (loading part).
- 6) Tap the button located in the upper side of the No. of test cartridge region to select the ID chip that you want to use.
- 7) When the selected cartridge slot is activated, set the number of the detector tube by tapping.
- 8) Set the number of pipette tips by tapping.
- 9) Tap the 'Start' button on the left upper of the main screen to start test.

INTERPRETATION OF TEST RESULT

- Instrument for ichroma™ tests calculates the test result

automatically and displays AFP concentration of the test sample in terms of ng/mL.

- Reference range: < 7.8 ng/mL
- Working range: 5 - 350 ng/mL

QUALITY CONTROL

- Quality control tests are a part of the good testing practice to confirm the expected results and validity of the assay and should be performed at regular intervals.
- Quality control tests should also be performed whenever there is any question concerning the validity of the test results.
- Control materials are provided on demand with **ichroma™ AFP Neo**. For more information regarding obtaining the control materials, contact Boditech Med Inc.'s Sales Division for assistance.
(Please refer to the instructions for use of control material.)

PERFORMANCE CHARACTERISTICS

■ **Analytical sensitivity**

Limit of Blank (LoB)	0.87 ng/mL
Limit of Detection (LoD)	1.31 ng/mL
Limit of Quantitation (LoQ)	5.0 ng/mL

■ **Analytical specificity**

- Cross-reactivity
Biomolecules listed in the following table were added to the test sample(s) at concentrations much higher than their normal physiological levels in the blood. **ichroma™ AFP Neo** test results did not show any significant cross-reactivity with these biomolecules.

Cross-reactants	Concentration
CEA	500 ng/mL
PSA	400 ng/mL
ALP	200 U/L
Albumin	60 g/L

- Interference
Interferents listed in the following table were added to the test sample at the concentration mentioned below. **ichroma™ AFP Neo** test results did not show any significant interference with these materials.

Interferents	Concentration
Hemoglobin	10 g/L
Bilirubin, unconjugated	684 µmol/L
Triglycerides	1500 mg/dL
Ascorbic acid	5.25 mg/dL
Glucose	1000 mg/dL

■ **Precision**

- Single-site study
Repeatability (within-run precision)
within-laboratory precision (Total precision)
Lot to lot precision

3 Lots of **ichroma™ AFP Neo** were tested for 20 days. Each standard material was tested 2 times per day. For each test, each material was duplicated.

AFP [ng/mL]	Single-site study					
	Repeatability		Within-laboratory precision		Lot to lot precision	
	AVG [ng/mL]	CV (%)	AVG [ng/mL]	CV (%)	AVG [ng/mL]	CV (%)

7.5	7.43	6.47	7.48	5.89	7.51	5.39
20	19.70	5.76	19.80	5.66	20.00	5.77
200	200.66	5.79	200.13	5.83	201.17	5.66

- Multi-site study

Reproducibility

1 Lot of **ichroma™ AFP Neo** was tested for 5 days in 3 different sites (1 person per 1 site, 1 instrument per 1 site). Each standard material was tested 1 time per and 5 replicates per day.

Multi-site study		
AFP [ng/mL]	Reproducibility	
	AVG [ng/mL]	CV (%)
7.5	7.39	6.03
20	19.91	5.73
200	200.8	6.21


■ Accuracy

The accuracy was confirmed by testing with 3 different lots of **ichroma™ AFP Neo**. The tests were repeated 10 times at each concentration of the control standard.

AFP [ng/mL]	Lot 1	Lot 2	Lot 3	AVG [ng/mL]	Recovery (%)
200.0	203.85	200.04	203.70	202.53	101
180.8	183.06	180.38	182.35	181.93	101
140.8	143.43	142.66	142.26	142.78	101
66.7	65.59	66.58	66.19	66.12	99
26.8	26.46	26.75	26.72	26.64	100
7.5	7.57	7.42	7.53	7.51	100

■ Comparability

AFP concentrations of 100 clinical samples were quantified independently with **ichroma™ AFP Neo** (**ichroma™ II**) and **comparator A** as per prescribed test procedures. Test results were compared, and their comparability was investigated with linear regression and correlation coefficient (R). The regression equation and correlation coefficient are as follow.



REFERENCES

1. Tartarinov, Y.S. Detection of embryospecific alpha-globulin in the blood sera of patients with primary liver tumor. *Vopr. Med. Khim.* 10:90-91 (1964).
2. McIntire, K.R., Waidmann, T.A., Moertel, C.G. and Go, V.L.W. Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract. *Cancer Res.* 35:991-996 (1975).
3. Javadpouf, N., McIntire, K.R. and Waidmann, T.A. Human chorionic gonadotropin (HCG) and alpha-fetoprotein (AFP) in sera and tumor cells of patients with testicular seminoma. *Cancer* 42:2768-2772. (1978).
4. Chen, D.S. and Sung, J.L. Relationship of Hepatitis B Surface Antigen to serum alpha-fetoprotein in nonmalignant diseases of the liver. *Cancer* 44:984-992 (1979).
5. Rhoslati, E. and Seppala, M. studies of carcinofoetal proteins: Physical and Chemical Properties of Human alpha-

fetoprotein. *Int. J. Cancer* 7:218-225 (1971).

6. Abelev, G.I. Alpha-fetoprotein in oncogenesis and its association with malignant tumors. *Adv. Cancer Res.* 7:295-358 (1971).
7. Wespic, H.C. Alpha-fetoprotein: its quantification and relationship to neoplastic disease, pp 115-129 In *Alpha-fetoprotein, Laboratory Procedures and Clinical Applications*, Kirkpatrick, A. and Nakamura R (eds.), Masson Publishing, New York (1981) After Radical Prostatectomy. *J. Urol.* 142:1082-90 (1989).

Note: Please refer to the table below to identify various symbols.

	Sufficient for <n> tests
	Read instruction for use
	Use by Date
	Batch code
	Catalog number
	Caution
	Manufacturer
	Authorized representative of the European Community
	In vitro diagnostic medical device
	Temperature limit
	Do not reuse
	This product fulfills the requirements of the Directive 98/79/EC on in vitro diagnostic medical devices

For technical assistance, please contact:

Boditech Med Inc.'s Technical Services

Tel: +(82) -33-243-1400

E-mail: TS@boditech.co.kr



Boditech Med Inc.

43, Geodudanji 1-gil, Dongnae-myeon, Chuncheon-si, Gang-won-do, 24398, Republic of Korea

Tel: +(82) -33-243-1400

Fax: +(82) -33-243-9373

www.boditech.co.kr

EC REP

Obelis s.a.

Bd. Général Wahis 53, 1030 Brussels, Belgium

Tel: +(32) -2-732-59-54

Fax: +(32) -2-732-60-03

E-Mail: mail@obelis.net

